Zacks: Analysts Anticipate Phio Pharmaceuticals Corp. (NASDAQ:PHIO) to Post -$0.32 EPS

Wall Street analysts predict that Phio Pharmaceuticals Corp. (NASDAQ:PHIO) will announce earnings per share of ($0.32) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Phio Pharmaceuticals’ earnings. Phio Pharmaceuticals posted earnings per share of ($0.41) in the same quarter last year, which indicates a positive year over year growth rate of 22%. The firm is expected to report its next earnings results on Thursday, March 24th.

On average, analysts expect that Phio Pharmaceuticals will report full year earnings of ($1.11) per share for the current financial year. For the next fiscal year, analysts expect that the firm will post earnings of $0.98 per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Phio Pharmaceuticals.

Phio Pharmaceuticals (NASDAQ:PHIO) last issued its quarterly earnings results on Wednesday, November 10th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03).

Several analysts have issued reports on PHIO shares. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Phio Pharmaceuticals in a research note on Monday, November 15th. Zacks Investment Research lowered Phio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, November 17th.

PHIO traded down $0.02 on Thursday, hitting $1.42. 80,283 shares of the company were exchanged, compared to its average volume of 760,139. Phio Pharmaceuticals has a 12 month low of $1.32 and a 12 month high of $4.36. The company has a market cap of $19.22 million, a PE ratio of -1.17 and a beta of 1.96. The stock’s fifty day moving average is $1.75 and its 200-day moving average is $1.92.

A number of large investors have recently modified their holdings of PHIO. Virtu Financial LLC acquired a new stake in shares of Phio Pharmaceuticals in the 1st quarter valued at $42,000. Goldman Sachs Group Inc. acquired a new stake in shares of Phio Pharmaceuticals in the 2nd quarter valued at $43,000. Cetera Investment Advisers acquired a new stake in shares of Phio Pharmaceuticals in the 3rd quarter valued at $61,000. Dimensional Fund Advisors LP boosted its holdings in shares of Phio Pharmaceuticals by 38.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 34,808 shares of the company’s stock valued at $93,000 after purchasing an additional 9,631 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Phio Pharmaceuticals by 330.6% in the 1st quarter. Geode Capital Management LLC now owns 87,501 shares of the company’s stock valued at $234,000 after purchasing an additional 67,182 shares in the last quarter. 5.19% of the stock is currently owned by institutional investors and hedge funds.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Featured Story: What is the S&P/ASX 200 Index?

Get a free copy of the Zacks research report on Phio Pharmaceuticals (PHIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.